Merck (MRK)

AI-powered earnings call analysis for Merck. Get insights from quarterly earnings reports with our AI-generated podcast. Educational content only - not investment advice.

20 episodes 5 languages

Latest Episode

Q3 2026 Earnings

6:49 • 10/29/2026

Merck (MRK) - Q3 2026

0:00

6:49

Speed:

Q3 2026 Earnings

7:10 • 2026/10/29

Merck (MRK) - Q3 2026

0:00

7:10

Speed:

Q3 2026 Earnings

9:02 • 29/10/2026

Merck (MRK) - Q3 2026

0:00

9:02

Speed:

Q3 2026 Earnings

10:50 • 29/10/2026

Merck (MRK) - Q3 2026

0:00

10:50

Speed:

Q3 2026 Earnings

6:40 • 29.10.2026

Merck (MRK) - Q3 2026

0:00

6:40

Speed:

All Episodes

EN - English (4) CN - 中文 (4) FR - Français (4) ES - Español (4) DE - Deutsch (4)

Q3 2026 Earnings

6:49

Merck delivered Q3 2026 revenue of $18.1B (+5%), raised FY2026 EPS guidance to $2.77-$2.82, and achieved major Phase 3 wins for sac-TMT and entismodigene, positioning the company well beyond KEYTRUDA's loss of exclusivity.

Q2 2026 Earnings

6:45

Merck delivered Q2 revenue of $16.6B (+5% YoY) with raised full-year guidance to $66.3-67.3B, driven by KEYTRUDA strength, new launches, and multiple clinical wins including sac-TMT Phase III positivity.

Q1 2026 Earnings

7:04

Merck delivered 5% Q1 revenue growth to $16.3B driven by oncology and animal health strength, raised 2026 guidance despite a $9B Cidara acquisition charge, and positioned 20+ new launches as major growth drivers with $70B+ commercial potential by mid-2030s.